SMOFKABIVEN amino acids 5.1% / lipids 3.8% / glucose 12.7% / electrolytes 0.7% emulsion for intravenous infusion bag 986 mL Australia - Kiingereza - Department of Health (Therapeutic Goods Administration)

smofkabiven amino acids 5.1% / lipids 3.8% / glucose 12.7% / electrolytes 0.7% emulsion for intravenous infusion bag 986 ml

fresenius kabi australia pty ltd - medium chain triglycerides, quantity: 60 g/l; soya oil, quantity: 60 g/l; olive oil, quantity: 50 g/l; fish oil - rich in omega-3 acids, quantity: 30 g/l - injection, intravenous infusion - excipient ingredients: sodium oleate; egg lecithin; sodium hydroxide; glycerol; dl-alpha-tocopherol; water for injections - parenteral nutrition for adult patients and paediatric patients aged 2 years and above when oral or enteral nutrition is impossible, insufficient or contraindicated.

Potassium chloride 0.15% (potassium 20mmol/1litre) / Glucose 5% infusion 1litre Viaflo bags Uingereza - Kiingereza - MHRA (Medicines & Healthcare Products Regulatory Agency)

potassium chloride 0.15% (potassium 20mmol/1litre) / glucose 5% infusion 1litre viaflo bags

potassium 20mmol/1litre) / glucose 5% infusion 1litre viaflo bags (baxter healthcare ltd - potassium chloride; glucose anhydrous - infusion - 1.5mg/1ml ; 50mg/1ml

AVELOX IV 400 moxifloxacin 400 mg/250 mL (as hydrochloride) intravenous infusion solution bottle Australia - Kiingereza - Department of Health (Therapeutic Goods Administration)

avelox iv 400 moxifloxacin 400 mg/250 ml (as hydrochloride) intravenous infusion solution bottle

bayer australia ltd - moxifloxacin, quantity: 1.6 mg/ml (equivalent: moxifloxacin hydrochloride, qty 1.744 mg/ml) - injection, intravenous infusion - excipient ingredients: hydrochloric acid; sodium chloride; water for injections; sodium hydroxide - avelox (moxifloxacin hydrochloride) tablets are indicated for the treatment of adults with infections caused by susceptible organisms in the conditions. acute bacterial sinusitis, community acquired pneumonia, acute exacerbations of chronic bronchitis. avelox iv (moxifloxacin hydrochloride) intravenous solutions are indicated for treatment of adults who require initial iv therapy for the treatment of infections in the conditions. community acquired pneumonia (caused by susceptible organisms). acute exacerbations of chronic bronchitis when caused by organisms bacteriologically proven to be resistant to other classes of antibiotics or when there is intolerance to other antibiotics. avelox iv (moxifloxacin hydrochloride) intravenous solutions are indicated for treatment of adults with severe and complicated skin and skin structure infections who require initial parenteral therapy, and who have intolerance to alternative agents. (especially penicillin allergy), and when caused by organisms known to be susceptible to moxifloxacin. appropriate culture and susceptibility tests should be performed before treatment in order to isolate and identify organisms causing infection and to determine their susceptibility to moxifloxacin. therapy with moxifloxacin may be initiated. in some conditions, before results of these tests are known. once results become available, therapy should be continued with the most appropriate antibiotic therapy.

AVELOX IV 400 moxifloxacin 400 mg/250 mL (as hydrochloride) intravenous infusion solution bag Australia - Kiingereza - Department of Health (Therapeutic Goods Administration)

avelox iv 400 moxifloxacin 400 mg/250 ml (as hydrochloride) intravenous infusion solution bag

bayer australia ltd - moxifloxacin, quantity: 1.6 mg/ml (equivalent: moxifloxacin hydrochloride, qty 1.744 mg/ml) - injection, intravenous infusion - excipient ingredients: water for injections; sodium chloride; sodium hydroxide; hydrochloric acid - avelox (moxifloxacin hydrochloride) tablets are indicated for the treatment of adults with infections caused by susceptible organisms in the conditions. acute bacterial sinusitis, community acquired pneumonia, acute exacerbations of chronic bronchitis. avelox iv (moxifloxacin hydrochloride) intravenous solutions are indicated for treatment of adults who require initial iv therapy for the treatment of infections in the conditions. community acquired pneumonia (caused by susceptible organisms). acute exacerbations of chronic bronchitis when caused by organisms bacteriologically proven to be resistant to other classes of antibiotics or when there is intolerance to other antibiotics. avelox iv (moxifloxacin hydrochloride) intravenous solutions are indicated for treatment of adults with severe and complicated skin and skin structure infections who require initial parenteral therapy, and who have intolerance to alternative agents. (especially penicillin allergy), and when caused by organisms known to be susceptible to moxifloxacin. appropriate culture and susceptibility tests should be performed before treatment in order to isolate and identify organisms causing infection and to determine their susceptibility to moxifloxacin. therapy with moxifloxacin may be initiated. in some conditions, before results of these tests are known. once results become available, therapy should be continued with the most appropriate antibiotic therapy.

BAXTER 10% ANHYDROUS GLUCOSE 1000mL injection AHB0164 Australia - Kiingereza - Department of Health (Therapeutic Goods Administration)

baxter 10% anhydrous glucose 1000ml injection ahb0164

baxter healthcare pty ltd - glucose, quantity: 100 g/l - injection, intravenous infusion - excipient ingredients: water for injections - this product accepted for registration/listing as 'currently supplied' at the time of commencement of the act. indications held in artg paper records. (old code)

GLUCOSE 5% 50 g/1000 mL glucose injection bag Australia - Kiingereza - Department of Health (Therapeutic Goods Administration)

glucose 5% 50 g/1000 ml glucose injection bag

fresenius kabi australia pty ltd - glucose, quantity: 50 g - injection, intravenous infusion - excipient ingredients: water for injections; hydrochloric acid; sodium hydroxide - the solutions are indicated for intravenous fluid therapy designed to correct deficiencies in energy levels. glucose 5% is also used to correct hydration levels. the solutions may also be used as solvents for intravenously administered drugs where compatibility has been established.

GLUCOSE 10% 50g/500mL injection bag Australia - Kiingereza - Department of Health (Therapeutic Goods Administration)

glucose 10% 50g/500ml injection bag

fresenius kabi australia pty ltd - glucose, quantity: 50 g - injection, intravenous infusion - excipient ingredients: water for injections; hydrochloric acid; sodium hydroxide - the solutions are indicated for intravenous fluid therapy designed to correct deficiencies in energy levels. glucose 5% is also used to correct hydration levels. the solutions may also be used as solvents for intravenously administered drugs where compatibility has been established.

GLUCOSE 5% 25 g/500 mL glucose injection bag Australia - Kiingereza - Department of Health (Therapeutic Goods Administration)

glucose 5% 25 g/500 ml glucose injection bag

fresenius kabi australia pty ltd - glucose, quantity: 25 g - injection, intravenous infusion - excipient ingredients: water for injections; sodium hydroxide; hydrochloric acid - the solutions are indicated for intravenous fluid therapy designed to correct deficiencies in energy levels. glucose 5% is also used to correct hydration levels. the solutions may also be used as solvents for intravenously administered drugs where compatibility has been established.

BAXTER 10% ANHYDROUS GLUCOSE 500mL injection AHB0163 Australia - Kiingereza - Department of Health (Therapeutic Goods Administration)

baxter 10% anhydrous glucose 500ml injection ahb0163

baxter healthcare pty ltd - glucose, quantity: 100 g/l - injection, intravenous infusion - excipient ingredients: water for injections - this product accepted for registration/listing as 'currently supplied' at the time of commencement of the act. indications held in artg paper records. (old code)

PLASMA-LYTE 148 and 5% GLUCOSE 1000mL injection bag AHB2584 Australia - Kiingereza - Department of Health (Therapeutic Goods Administration)

plasma-lyte 148 and 5% glucose 1000ml injection bag ahb2584

baxter healthcare pty ltd - sodium acetate, quantity: 3.68 g/l; potassium chloride, quantity: 370 mg/l; glucose, quantity: 50 g/l; magnesium chloride hexahydrate, quantity: 300 mg/l; sodium gluconate, quantity: 5.02 g/l; sodium chloride, quantity: 5.26 g/l - injection, intravenous infusion - excipient ingredients: hydrochloric acid; water for injections - plasma-lyte 148 and 5% glucose iv infusion is indicated as a source of water, electrolytes and calories or as an alkalinising agent. plasma-lyte 148 and 5% glucose iv infusion is indicated as a source of water and electrolytes or as an alkalinising agent.